Egg yolk sialylglycopeptide: purification, isolation and characterization of N-glycans from minor glycopeptide species

Sialylglycopeptide (SGP) is a readily available naturally occurring glycopeptide obtained from hen egg yolk which is now commercially available. During SGP extraction, other minor glycopeptide species are identified, bearing N-glycan structures that might be of interest, such as asymmetrically branched and triantennary glycans. As the scale of SGP production increases, recovery of minor glycopeptides and their N-glycans can become more feasible. In this paper, we aim to provide structural characterization of the N-glycans derived from these minor glycopeptides.

Automation of Immunoglobulin Glycosylation Analysis

The development of reliable, affordable, high-resolution glycomics technologies that can be used for many samples in a high-throughput manner are essential for both the optimization of glycosylation in the biopharmaceutical industry as well as for the advancement of clinical diagnostics based on glycosylation biomarkers. We will use this chapter to review the sample preparation processes that have been used on liquid-handling robots to obtain high-quality glycomics data for both biopharmaceutical and clinical antibody samples. This will focus on glycoprotein purification, followed by glycan or glycopeptide generation, derivatization and enrichment. The use of liquid-handling robots for glycomics studies on other sample types beyond antibodies will not be discussed here. We will summarize our thoughts on the current status of the field and explore the benefits and challenges associated with developing and using automated platforms for sample preparation. Finally, the future outlook for the automation of glycomics will be discussed along with a projected impact on the field in general.

Recognition of Dimeric Lewis X by Anti-Dimeric Lex Antibody SH2

The carbohydrate antigen dimeric Lewis X (DimLe^x), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics. Using the native DimLe^x antigen as a vaccine would elicit an autoimmune response against the Le^x antigen found on normal, healthy cells. Thus, we aim to study the immunogenic potential of DimLe^x and search internal epitopes displayed by DimLe^x that remain to be recognized by anti-DimLe^x monoclonal antibodies (mAbs) but no longer possess epitopes recognized by anti-Le^x mAbs. In this context, we attempted to map the epitope recognized by anti-DimLe^x mAb SH2 by titrations and competitive inhibition experiments using oligosaccharide fragments of DimLe^x as well as Le^x analogues. We compare our results with that reported for anti-Le^x mAb SH1 and anti-polymeric Le^x mAbs 1G5F6 and 291-2G3-A. While SH1 recognizes an epitope localized to the non-reducing end Le^x trisaccharide, SH2, 1G5F6, and 291-2G3-A have greater affinity for DimLe^x conjugates than for Le^x conjugates. We show, however, that the Le^x trisaccharide is still an important recognition element for SH2, which (like 1G5F6 and 291-2G3-A) makes contacts with all three sugar units of Le^x. In contrast to mAb SH1, anti-polymeric Le^x mAbs make contact with the GlcNAc acetamido group, suggesting that epitopes extend further from the non-reducing end Le^x. Results with SH2 show that this epitope is only recognized when DimLe^x is presented by glycoconjugates. We have reported that DimLe^x adopts two conformations around the β-d-GlcNAc-(1→3)-d-Gal bond connecting the Le^x trisaccharides. We propose that only one of these conformations is recognized by SH2 and that this conformation is favored when the hexasaccharide is presented as part of a glycoconjugate such as DimLe^x-bovine serum albumin (DimLe^x-BSA). Proper presentation of the oligosaccharide candidate via conjugation to a protein or lipid is essential for the design of an anti-cancer vaccine or immunotherapeutic based on DimLe^x.